Clinical Trials and Expanded Access Policy
ImmPACT Bio is committed to providing transformative therapies to patients who have exhausted available treatment options. Participation in clinical trials is the best way to access our investigational products.
Expanded access is the use of an investigational product outside of a clinical trial for the treatment of a serious or life-threatening condition. When participating in a clinical study is not possible, ImmPACT Bio may consider requests for expanded access in rare circumstances when an individual has no other comparable or satisfactory alternative therapy options available or is not eligible to participate in a current clinical trial, and where the potential benefits of the investigational product are greater than the known risks of the disease. Patients interested in seeking expanded access should talk to their doctors about whether it is right for them. Treating physicians can find more information on our ongoing clinical trials by visiting www.clinicaltrials.gov and search for ImmPACT Bio, or by clicking here:
Study Details | Study of IMPT-314 in R/R Aggressive B-cell | ClinicalTrials.gov
Treating physicians can also request information about our clinical trials or expanded access by contacting ImmPACT Bio at clinicaltrials@immpact-bio.com. ImmPACT Bio will acknowledge inquiries as soon as possible, usually within 5 business days of receipt.
Pursuant to the 21st Century Cures Act, ImmPACT Bio may revise this policy at any time and this policy shall not serve as a guarantee of access to any specific investigational therapy by any individual.
